Get the Stockscreener App
0.5578
1.05%
0.0058
Pre-market:
.54
-0.0178
-3.19%
Ensysce Biosciences Inc stock is traded at $0.5578, with a volume of 169.91K.
It is up +1.05% in the last 24 hours and up +40.68% over the past month.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
See More
Previous Close:
$0.552
Open:
$0.551
24h Volume:
169.91K
Relative Volume:
0.03
Market Cap:
$2.03M
Revenue:
$4.49M
Net Income/Loss:
$-10.97M
P/E Ratio:
-0.0915
EPS:
-6.0969
Net Cash Flow:
$-7.17M
1W Performance:
-11.64%
1M Performance:
+40.68%
6M Performance:
-75.32%
1Y Performance:
-84.06%
1-Day Range:
$0.5401
$0.5778
1-Week Range:
$0.515
$0.6099
52-Week Range:
$0.3144
$4.85
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Name
Ensysce Biosciences Inc
Sector
Industry
Phone
(858) 263-4196
Address
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.5578 | 2.03M | 4.49M | -10.97M | -7.17M | -6.0969 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Ensysce Biosciences Inc Stock (ENSC) Latest News
Weekly Trades: Is Ensysce Biosciences Inc a turnaround story2026 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Ensysce Biosciences Files Certificate of Correction for Series B Preferred Stock with Delaware Secretary of State - Minichart
Ensysce Biosciences files correction to Series B preferred stock designation By Investing.com - Investing.com South Africa
Ensysce Biosciences Corrects Series B Preferred Stock Designation - TipRanks
Ensysce Biosciences files correction to Series B preferred stock designation - Investing.com
Ensysce Biosciences (ENSC) files correction to Series B preferred stock - Stock Titan
If You Invested $1,000 in Ensysce Biosciences Inc (ENSC) - Stock Titan
ENSC Stock Price, Quote & Chart | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Earnings Recap: Is Travere Therapeutics Inc stock heavily shorted2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Risk Analysis: Is Ensysce Biosciences Inc being accumulated by smart money2026 Setups & Daily Profit Focused Screening - baoquankhu1.vn
Ensysce Biosciences Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Market Fear: Will Ensysce Biosciences Inc benefit from geopolitical trendsJuly 2025 Setups & Smart Swing Trading Alerts - baoquankhu1.vn
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Pl - PharmiWeb.com
CEO takes live questions on Ensysce PF614 pain-drug plans - Stock Titan
Ensysce publishes phase 1 data on overdose-limiting opioid tech By Investing.com - Investing.com Australia
ENSC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Ensysce publishes phase 1 data on overdose-limiting opioid tech - Investing.com India
New opioid design limits drug release when too many pills are swallowed - Stock Titan
Promising Penny Stocks To Add to Your Watchlist – March 1st - Defense World
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Down 15.8% in February - Defense World
Dow Dips Over 600 Points; US Producer Prices Increase In January - Sahm
Top Penny Stocks To Follow TodayFebruary 27th - MarketBeat
Ensysce Biosciences Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Ensysce Biosciences (ENSC) over sub-$1 minimum bid price - Stock Titan
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Corsicana Daily Sun
Opioid safety drug developer Ensysce explores deals, possible asset sales - Stock Titan
Market Overview: Is Ensysce Biosciences Inc subject to activist investor interest2025 Market Outlook & Weekly Watchlist of Top Performers - baoquankhu1.vn
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Corsicana Daily Sun
Drug developer Ensysce invited to 2026 pain and substance use research forums - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Can Ensysce Biosciences Inc. continue delivering strong returnsJuly 2025 Momentum & Reliable Entry Point Alerts - mfd.ru
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Ensysce Biosciences files to sell 29.47M shares of common stock for holders - Intellectia AI
Why Ensysce Biosciences Inc. stock remains a top recommendationDip Buying & Free Community Consensus Stock Picks - mfd.ru
Why Ensysce Biosciences Inc. stock is a must watch in 2025Trade Entry Report & Daily Volume Surge Trade Alerts - mfd.ru
ENSC Should I Buy - Intellectia AI
Is Ensysce Biosciences Inc. subject to activist investor interestQuarterly Performance Summary & Verified Technical Signals - mfd.ru
RSI Check: Will Ensysce Biosciences Inc benefit from geopolitical trends2025 Trading Volume Trends & Weekly Sector Rotation Insights - baoquankhu1.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Ensysce Biosciences Reaches 50% Enrollment Milestone In Pivotal Phase 3 Trial Of PF614 - Nasdaq
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Does Ensysce Biosciences Inc. meet Warren Buffett’s criteriaEarnings Risk Summary & Capital Efficient Trade Techniques - mfd.ru
Ensysce Biosciences CEO says 'positioned for continued momentum' - MSN
Ensysce Biosciences reaches 50% enrollment in Phase 3 pain drug trial By Investing.com - Investing.com South Africa
New Highs: Does JPMPRM outperform in volatile marketsTrade Volume Report & Stock Timing and Entry Methods - baoquankhu1.vn
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):